{"id":1166,"date":"2026-05-08T20:18:48","date_gmt":"2026-05-08T20:18:48","guid":{"rendered":"http:\/\/elmoustkbal.com\/?p=1166"},"modified":"2026-05-08T20:18:48","modified_gmt":"2026-05-08T20:18:48","slug":"f-percentage-of-aggresome-positive-cells-in-h226-cells-after-treatment-with-either-bzcamsaha-or-bzcam-pre-treated-with-hdac6-sirna-or-control-sirna","status":"publish","type":"post","link":"https:\/\/elmoustkbal.com\/?p=1166","title":{"rendered":"\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA"},"content":{"rendered":"<p>\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA. apoptosis was induced by <a href=\"https:\/\/www.adooq.com\/l-lysine-thioctate.html\">L-Lysine thioctate<\/a> the combination of vorinostat [suberoylanilide hydroxamic acid (SAHA); potently inhibits HDAC6] with CAM and <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?db=gene&#038;cmd=Retrieve&#038;dopt=full_report&#038;list_uids=3091\">HIF1A<\/a> BZ compared with each reagent or a 2-reagent combination. CAM\/BZ treatment induced vimentin positive-aggresome formation along with the accumulation of autolysosomes in the perinuclear region, whereas they were inhibited in the presence of SAHA. The SAHA\/CAM\/BZ combination treatment maximally upregulated genes related to ER stress including C\/EBP homologous protein (CHOP). Similarly to MM cell lines, enhanced cytotoxicity with CHOP upregulation following SAHA\/CAM\/BZ treatment was shown by a wild-type murine embryonic fibroblast (MEF) cell line; however, a CHOP-deficient MEF cell line almost completely canceled this pronounced cytotoxicity. Knockdown of HDAC6 with siRNA exhibited further enhanced CAM\/BZ-induced cytotoxicity and CHOP induction along with the cancellation of aggresome formation. Targeting the integrated networks of aggresome, proteasome, and autophagy is suggested to induce efficient ER stress-mediated apoptosis in MM cells. Keywords:multiple myeloma, aggresome, proteasome, autophagy, ER stress == Introduction == Multiple myeloma (MM) is a refractory hematopoietic malignancy showing clonal plasma cell accumulation. A major breakthrough in MM treatment has been the introduction of the first-in-class proteasome inhibitor bortezomib (BZ) (1,2). Moreover, the treatment of relapsed and refractory MM is now possible with carfilzomib, a second-generation proteasome inhibitor, and immunomodulatory agents. This has offered new alternatives for vulnerable patients (3,4). However, patients with relapsed and refractory MM are still urgent issues and require treatment combinations (5,6). Increasing lines of evidence indicate that proteasome inhibition induces misfolded protein accumulation in the endoplasmic reticulum (ER) (7,8). This evokes ER stress followed by the unfolded protein response (UPR) (9,10). UPR mainly functions: i) to decrease protein entry into the ER by suppressing translational rate; and ii) to increase the folding capacity of the ER via chaperon protein translational activations. L-Lysine thioctate Following incorrect folding in the ER, proteins are retro-translocated for degradation in the cytoplasm via the ubiquitin (Ub)-proteasome pathway [i.e., ER-associated degradation (ERAD)]. A failure in all the adaptation strategies triggers apoptosis and induces C\/EBP homologous protein (CHOP) (GADD153), a pro-apoptotic transcription factor and other pathways (710). Since MM is characterized by the uncontrolled cell growth of monoclonal antibody (mAb)-producing plasma cells, production of large quantities of unfolded or misfolded immunoglobulin triggers ER stress. Thus, therapeutic manipulation of the UPR pathway appears to disrupt cellular mechanisms for processing high protein loads and cellular stress, and further leads to death of MM cells. Macroautophagy (hereafter, autophagy) occurs when cellular proteins and organelles (e.g., ER) are enveloped in an autophagosome and degraded in lysosomes by lysosomal hydrolases (11,12). Although autophagy is considered a bulk non-selective degradation of long-lived proteins and organelles, recent reports revealed the selective degradation pathway of ubiquitinated protein via autophagy using docking proteins (e.g., p62) and related proteins (e.g., NBR1), having both a microtubule-associated protein 1 light chain 3 (LC3)-interacting region and a Ub-associated domain (13,14). Thus, overflowed ubiquitinated proteins are bound to p62 and subsequently engulfed into an autophagosome via the LC3-interacting region in p62. This indicates that autophagy also acts as a compensatory degradation system when the proteasome system is impaired (14). We previously reported that the inhibition of autophagy using the autophagy inhibitor bafilomycin A1(BAF) enhanced BZ-induced apoptosis by burdening ER stress in MM cell lines (15). We also reported that macrolide antibiotics [e.g., clarithromycin (CAM) and azithromycin (AZM)] attenuated or blocked autophagy flux, possibly mediated through the inhibition of the lysosomal function, and that L-Lysine thioctate ER stress loading was enhanced by both the BZ-induced inhibition of the Ub-proteasome system and the CAM- or AZM-induced inhibition of the autophagy-lysosome system. This is followed by CHOP transcriptional activation and the induction of apoptosis in MM and breast cancer cells (16,17). Therefore, concomitant blocking of proteasome and autophagy appears to be a promising combination therapy. Moreover, misfolded\/unfolded proteins are sequestrated into aggregates and transported. They are then discarded from the cytoplasm by dynein motors through the microtubule network to the aggresome (18). The class II histone deacetylase 6 (HDAC6), which is a microtubule-associated deacetylase and an aggresome component, has the capacity to bind both polyubiquitinated misfolded proteins and dynein motors (19). By acting as an adaptor between ubiquitinated protein aggregates and dynein, HDAC6 enables aggregated protein loading onto the dynein motor protein complex (20). Thus, in the formation of aggresome at L-Lysine thioctate the microtubule-organizing center (MTOC), HDAC6, dynein, and polyubiquitinated proteins functionally interact with each other (19,20). If HDAC6 is lacking, cells will not be able to clear cytoplasmic unfolded protein aggregates; cells cannot appropriately form aggresomes; and cells become hypersensitive to unfolded protein accumulation (19). Therefore, HDAC6 appears to be another critical factor in the management of unfolded protein-induced stress at the cellular level. Moreover, some parts of the aggresome are reported to be degraded via the autophagy-lysosome system (21,22). A recent study also revealed that p62 regulates the accumulation and autophagic clearance of protein.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA. apoptosis was induced&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"class_list":["post-1166","post","type-post","status-publish","format-standard","hentry","category-potassium-channels-non-selective"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA - DHFR inhibitors in non-small cell lung cancer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/elmoustkbal.com\/?p=1166\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA - DHFR inhibitors in non-small cell lung cancer\" \/>\n<meta property=\"og:description\" content=\"\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA. apoptosis was induced&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/elmoustkbal.com\/?p=1166\" \/>\n<meta property=\"og:site_name\" content=\"DHFR inhibitors in non-small cell lung cancer\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-08T20:18:48+00:00\" \/>\n<meta name=\"author\" content=\"webmaster\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"webmaster\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=1166#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=1166\"},\"author\":{\"name\":\"webmaster\",\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/#\\\/schema\\\/person\\\/6ba91697c07f5b1e48a1c50fec2fd4a0\"},\"headline\":\"\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA\",\"datePublished\":\"2026-05-08T20:18:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=1166\"},\"wordCount\":848,\"articleSection\":[\"Potassium Channels, Non-selective\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=1166\",\"url\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=1166\",\"name\":\"\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA - DHFR inhibitors in non-small cell lung cancer\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/#website\"},\"datePublished\":\"2026-05-08T20:18:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/#\\\/schema\\\/person\\\/6ba91697c07f5b1e48a1c50fec2fd4a0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=1166#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/elmoustkbal.com\\\/?p=1166\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=1166#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/elmoustkbal.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/#website\",\"url\":\"https:\\\/\\\/elmoustkbal.com\\\/\",\"name\":\"DHFR inhibitors in non-small cell lung cancer\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/elmoustkbal.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/#\\\/schema\\\/person\\\/6ba91697c07f5b1e48a1c50fec2fd4a0\",\"name\":\"webmaster\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/66fbd3a9ef48c403fd533a73978e5557cc8b799f7e461809e4f768dafe87f404?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/66fbd3a9ef48c403fd533a73978e5557cc8b799f7e461809e4f768dafe87f404?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/66fbd3a9ef48c403fd533a73978e5557cc8b799f7e461809e4f768dafe87f404?s=96&d=mm&r=g\",\"caption\":\"webmaster\"},\"sameAs\":[\"http:\\\/\\\/elmoustkbal.com\"],\"url\":\"https:\\\/\\\/elmoustkbal.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA - DHFR inhibitors in non-small cell lung cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/elmoustkbal.com\/?p=1166","og_locale":"en_US","og_type":"article","og_title":"\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA - DHFR inhibitors in non-small cell lung cancer","og_description":"\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA. apoptosis was induced&hellip;","og_url":"https:\/\/elmoustkbal.com\/?p=1166","og_site_name":"DHFR inhibitors in non-small cell lung cancer","article_published_time":"2026-05-08T20:18:48+00:00","author":"webmaster","twitter_card":"summary_large_image","twitter_misc":{"Written by":"webmaster","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/elmoustkbal.com\/?p=1166#article","isPartOf":{"@id":"https:\/\/elmoustkbal.com\/?p=1166"},"author":{"name":"webmaster","@id":"https:\/\/elmoustkbal.com\/#\/schema\/person\/6ba91697c07f5b1e48a1c50fec2fd4a0"},"headline":"\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA","datePublished":"2026-05-08T20:18:48+00:00","mainEntityOfPage":{"@id":"https:\/\/elmoustkbal.com\/?p=1166"},"wordCount":848,"articleSection":["Potassium Channels, Non-selective"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/elmoustkbal.com\/?p=1166","url":"https:\/\/elmoustkbal.com\/?p=1166","name":"\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA - DHFR inhibitors in non-small cell lung cancer","isPartOf":{"@id":"https:\/\/elmoustkbal.com\/#website"},"datePublished":"2026-05-08T20:18:48+00:00","author":{"@id":"https:\/\/elmoustkbal.com\/#\/schema\/person\/6ba91697c07f5b1e48a1c50fec2fd4a0"},"breadcrumb":{"@id":"https:\/\/elmoustkbal.com\/?p=1166#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/elmoustkbal.com\/?p=1166"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/elmoustkbal.com\/?p=1166#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/elmoustkbal.com\/"},{"@type":"ListItem","position":2,"name":"\ufeff(F) Percentage of aggresome-positive cells in H226 cells after treatment with either BZCAMSAHA or BZCAM pre-treated with HDAC6 siRNA or control siRNA"}]},{"@type":"WebSite","@id":"https:\/\/elmoustkbal.com\/#website","url":"https:\/\/elmoustkbal.com\/","name":"DHFR inhibitors in non-small cell lung cancer","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/elmoustkbal.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/elmoustkbal.com\/#\/schema\/person\/6ba91697c07f5b1e48a1c50fec2fd4a0","name":"webmaster","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/66fbd3a9ef48c403fd533a73978e5557cc8b799f7e461809e4f768dafe87f404?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/66fbd3a9ef48c403fd533a73978e5557cc8b799f7e461809e4f768dafe87f404?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/66fbd3a9ef48c403fd533a73978e5557cc8b799f7e461809e4f768dafe87f404?s=96&d=mm&r=g","caption":"webmaster"},"sameAs":["http:\/\/elmoustkbal.com"],"url":"https:\/\/elmoustkbal.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=\/wp\/v2\/posts\/1166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1166"}],"version-history":[{"count":1,"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=\/wp\/v2\/posts\/1166\/revisions"}],"predecessor-version":[{"id":1167,"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=\/wp\/v2\/posts\/1166\/revisions\/1167"}],"wp:attachment":[{"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}